Woodward-McMaster & Associates, Inc., St. Louis, Mo.
Woodward-Moorehouse, & Associates, Inc., Clifton, N.J.[2] (6-30-76).
Woodson-Tenent Laboratories, Memphis, Tenn.
Woodville Lime Products, Woodville, Ohio.
Wyoming, University of, Department of Botany, Laramie, Wyo.[3] (6-30-76).

Y

Yakima Testing Laboratory, Yakima, Wash.[2] (6-30-74).
Yale University, Department of Geology & Geophysics, New Haven, Conn.[2] (6-30-73).
Yale University, Greeley Laboratories, New Haven, Conn.[2] (6-30-77).
Yeshiva University, New York, N.Y.[3] (6-30-73).
Yule, Jordan, and Associates, Camp Hill, Pa.

Z

Zoecon Corp., Palo Alto, Calif.

(Secs. 8 and 9, 37 Stat. 318, as amended, sec. 106, 71 Stat. 33; 7 U.S.C. 161, 162, 150ee; 29 FR 16210, as amended; 37 FR 28464, 28477; 7 CFR 301.48, 301.72, 301.80, 301.81 and 301.85)

This document shall become effective March 1, 1973, when it shall supersede PP 639 dated April 20, 1972, and PP 639 amendment dated August 3, 1972.

Under the provisions of the regulations supplemental to the notices of quarantine cited herein, soil samples for processing, testing, or analysis may be moved interstate from any regulated area specified in the regulations to laboratories approved by the Deputy Administrator and so listed by him. A laboratory may be approved if a compliance agreement is signed; samples are packaged to prevent spilling of soil; and soil residues, hazardous water residues, and shipping containers are treated in accordance with specified procedures.

The Deputy Administrator of Plant Protection and Quarantine Programs has approved the above-listed laboratories as establishments which meet the qualifications required under the regulations. The listed establishments are, therefore, authorized to receive soil samples from the regulated areas specified in the regulations without certificates or permits attached.

With respect to the establishments added to the list of approved laboratories, this revision relieves certain restrictions presently imposed and should be made effective promptly in order to be of maximum benefit to persons subject to the restrictions that are being relieved.

Accordingly, it is found upon good cause under the administrative procedure provisions of 5 U.S.C. 553, that notice and other public procedure with respect to this amendment are impracticable and contrary to the public interest, and good cause is found for making it effective less than 30 days after publication in the FEDERAL REGISTER.

Done at Washington, D.C., this 23d day of February 1973.

LEO G. K. IVERSON,
Deputy Administrator, Plant Protection and Quarantine Programs.

NOTE: A date after a name indicates when the import permit expires.

[FR Doc.73-3850 Filed 3-2-73;8:45 am]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[DESI 10296; Docket No. FDC-D-523; NDA 10-296]

ELI LILLY AND CO.

Combination Drug Containing Diethylstilbestrol, Methyltestosterone and Reserpine for Oral Use; Notice of Withdrawal of Approval of New Drug Application

Correction

In FR Doc. 73-2311 appearing at page 3534 of the issue for Wednesday, February 7, 1973, in the fifth line of the last paragraph the effective date, reading "February 1, 1973.", should read "February 7, 1973.".

[Docket No. FDC-D-477; NADA 6-888V]

MEGASUL (NITROPHENIDE) PREMIX 25 PERCENT

Notice of Withdrawal of Approval of New Animal Drug Application

Correction

In FR Doc. 73-2312 appearing on page 3535 of the issue for Wednesday, February 7, 1973, at the end of the last paragraph the effective date, reading "March 9, 1973", should read "February 7, 1973.".

[DESI 6363; Docket No. FDC-D-532; NDA 12-399]

A. H. ROBINS CO.

Methocarbamol With Phenacetin, Aspirin, Hyoscyamine Sulfate and Phenobarbital; Withdrawal of Approval of New Drug Application

On November 15, 1972, there was published in the FEDERAL REGISTER (37 FR 24206) a notice of opportunity for hearing (DESI 6363) in which the Commissioner of Food and Drugs proposed to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) withdrawing approval of NDA 12-399 for Robaxisal-PH Tablets containing methocarbamol, phenacetin, aspirin, hyoscyamine sulfate, and phenobarbital; A. H. Robins Co., 1407 Cummings Drive, Richmond, VA 23220. The basis of the proposed action was the lack of substantial evidence that the drug is effective as a fixed combination for the uses recommended or suggested in its labeling and that each component of the combination drug contributes to the total effects claimed.

Neither A. H. Robins nor any other interested person filed a written appearance of election with respect to Robaxisal-PH Tablets as provided by said notice. The failure to file such an appearance constitutes an election by such persons not to avail themselves of the opportunity for a hearing.

[1] National Compliance Agreement—applies to all branch laboratories in conterminous United States.
[2] Authorized to receive unsterilized foreign samples only.
[3] Authorized to receive unsterilized foreign samples also.

Also included in the aforesaid notice was Robaxisal Tablets containg methocarbamol and aspirin (NDA 12-281). A. H. Robins Co. elected to avail itself of an opportunity for hearing concerning that drug. That request for a hearing is under review and will be the subject of a separate FEDERAL REGISTER notice.

All identical, related, or similar products, not the subject of an approved new drug application, are covered by the new drug application reviewed and are subject to this notice. See 21 CFR 130.40 (37 FR 23185, October 31, 1972). Any person who wishes to determine whether a specific product is covered by this notice should write to the Food and Drug Administration, Bureau of Drugs, Office of Compliance (BD-300), 5600 Fishers Lane, Rockville, Md. 20852.

The Commissioner of Food and Drugs, pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505, 52 Stat. 1053, as amended; 21 U.S.C. 355), and the Administrative Procedure Act (5 U.S.C. 554), and under authority delegated to him (21 CFR 2.120), finds that on the basis of new information before him with respect to the drug, evaluated together with the evidence available to him when the application was approved, there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

Therefore, pursuant to the foregoing findings, approval of new drug application 12-399 and all amendments and supplements applying thereto is withdrawn effective on March 5, 1973. Shipment in interstate commerce of the above-listed drug product or of any identical, related, or similar product, not the subject of an approved new drug application, is henceforth unlawful.

Dated: February 23, 1973.

WILLIAM F. RANDOLPH,
Acting Associate Commissioner for Compliance.

[FR Doc.73-4056 Filed 3-2-73;8:45 am]

[DESI 6902; Docket No. FDC-D-597; NDA NO. 6-902]

ROCHE LABORATORIES, DIVISION OF HOFFMANN-LA ROCHE

Capsules Containing Nicotinyl Alcohol as the Tartrate and Trimethobenzamide Hydrochloride; Opportunity for Hearing on Proposal To Withdraw Approval of New Drug Application

In a notice (DESI 6902) published in the FEDERAL REGISTER of September 18, 1970 (35 FR 14628) the Commissioner of Food and Drugs announced his conclusions pursuant to the evaluation of a report received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the drug described below, stating that the drug was regarded as possibly effective and lacking substantial evidence of effectiveness for the various labeled indications. The possibly effective indications have been reclassified as lacking substantial evidence of effectiveness in that no new

evidence of effectiveness of the drug has been submitted within the period provided.

NDA 12-410; Tigacol Capsules containing nicotinyl alcohol as the tartrate and trimethobenzamide hydrochloride; Roche Laboratories, Division of Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110.

Therefore, notice is given to the holder(s) of the new drug application(s) and to any other interested person that the Commissioner proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) withdrawing approval of the listed new drug application(s) and all amendments and supplements thereto on the grounds that new information before him with respect to the drug(s), evaluated together with the evidence available to him at the time of approval of the application(s), shows there is a lack of substantial evidence that the drug(s) will have all the effects purported or represented to have under the conditions of use prescribed, recommended, or suggested in the labeling.

All identical, related, or similar products, not the subject of an approved new drug application, are covered by the new drug application(s) reviewed. See 21 CFR 130.40 (37 FR 23185, October 31, 1972). Any manufacturer or distributor of such an identical, related, or similar product is an interested person who may in response to this notice submit data and information, request that the new drug application(s) not be withdrawn, request a hearing, and participate as a party in any hearing. Any person who wishes to determine whether a specific product is covered by this notice should write to the Food and Drug Administration, Bureau of Drugs, Office of Compliance (BD-300), 5600 Fishers Lane, Rockville, Md. 20852.

In accordance with the provisions of section 505 of the Act (21 U.S.C. 355) and the regulations promulgated thereunder (21 CFR Part 130), the Commissioner hereby gives the applicant(s) and any other interested person an opportunity for a hearing to show why approval of the new drug application(s) should not be withdrawn.

On or before April 4, 1973, the applicant(s) and any other interested person is required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-88, 5600 Fishers Lane, Rockville, Md. 20852, a written appearance electing whether or not to avail himself of the opportunity for a hearing. Failure of an applicant or any other interested person to file a written appearance of election within said 30 days will constitute an election by him not to avail himself of the opportunity for a hearing.

If no person elects to avail himself of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing approval of the application(s).

If an applicant or any other interested person elects to avail himself of the opportunity for a hearing, he must file, on or before April 4, 1973, a written appearance requesting the hearing, giving the reasons why approval of the new drug application(s) should not be withdrawn, together with a well-organized and full-factual analysis of the clinical and other investigational data he is prepared to prove in support of his opposition. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that a genuine and substantial issue of fact requires a hearing (21 CFR 130.14(b)).

If review of the data submitted by an applicant or any other interested person warrants the conclusion that there exists substantial evidence demonstrating the effectiveness of the product(s) for the labeling claims involved, the Commissioner will rescind this notice of opportunity for hearing.

If review of the data in the application(s) and data submitted by the applicant(s) or any other interested person in a request for a hearing, together with the reasoning and factual analysis in a request for a hearing, warrants the conclusion that no genuine and substantial issue of fact precludes the withdrawal of approval of the application(s), the Commissioner will enter an order of withdrawal making findings and conclusions on such data.

If, upon the request of the new drug applicant(s) or any other interested person, a hearing is justified, the issues will be defined, a hearing examiner will be named, and he shall issue, as soon as practicable after April 4, 1973, a written notice of the time and place at which the hearing will commence. All persons interested in identical, related, or similar products covered by the new drug application(s) will be afforded an opportunity to appear at the hearing, file briefs, present evidence, cross-examine witnesses, submit suggested findings of fact, and otherwise participate as a party. The hearing contemplated by this notice will be open to the public except that any portion of the hearing that concerns a method or process the Commissioner finds entitled to protection as a trade secret will not be open to the public, unless the respondent specifies otherwise in his appearance.

Requests for a hearing and/or elections not to request a hearing may be seen in the Office of the Hearing Clerk (address given above) during regular business hours, Monday through Friday.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505, 52 Stat. 1052-53, as amended; 21 U.S.C. 355), and the Administrative Procedure Act (5 U.S.C. 554), and under authority delegated to the Commissioner (21 CFR 2.120).

Dated: February 23, 1973.

WILLIAM F. RANDOLPH,
Acting Associate Commissioner for Compliance.

[FR Doc.73-4055 Filed 3-2-73;8:45 am]

[FAP 3A2885]

G. D. SEARLE & CO.

Notice of Filing of Petition for Food Additive

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786; 21 U.S.C. 348(b)(5)), notice is given that a petition (FAP 3A2885) has been filed by G. D. Searle & Co., Box 5110, Chicago, IL 60680, proposing the issuance of a food additive regulation (21 CFR Part 121) to provide for the safe use of aspartame (L-aspartyl-L-phenylalanine methyl ester) in foods as a nutritive substance with intense sweetness and with flavor-enhancing properties.

Dated: March 1, 1973.

WILLIAM F. RANDOLPH,
Acting Associate Commissioner for Compliance.

[FR Doc.73-4260 Filed 3-2-73;8:45 am]

National Institutes of Health

PANCREAS WORKING GROUP

Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of The Pancreas Working Group, March 6, 1973, at 9 a.m. in the Montgomery Room at the Holiday Inn, Bethesda, Md. This meeting will be open to the public from 9 a.m., March 6, 1973, to discuss new approaches to management of cancer of the pancreas. Attendance by the public will be limited to space available.

Mr. Frank Karel, Associate Director of Public Affairs, NCI, Building 31, Room 10A31, National Institutes of Health, Bethesda, Md. 20014 (301/496-1911) will furnish summaries of the open meeting and roster of working group members.

Dr. John T. Kalberer, Jr., Special Assistant to the Director, Division of Cancer Grants, NCI, Building 31, Room 10A06, National Institutes of Health, Bethesda, Md. 20014 (301/496-5147) will provide substantive program information.

Dated: February 26, 1973.

JOHN F. SHERMAN,
Acting Director, NIH.

[FR Doc.73-4167 Filed 3-1-73;8:45 am]

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of Assistant Secretary for Housing Production and Mortgage Credit

[Docket No. N-73-127]

FIRE PROTECTION STANDARDS

Proposed Revision of HUD's Minimum Property Standards

Notice is hereby given that the Department of Housing and Urban Development proposes to revise its Minimum Property Standards for fire protection. The new fire protection standards would be Revision No. 1 to each of the following two proposed Minimum Property

Standards volumes for which a notice of availability was published in the FEDERAL REGISTER on November 29, 1972 (37 FR 25271):

HUD 4910 Minimum Property Standards for Multifamily Housing.
HUD 4920 Minimum Property Standards for Care-Type Housing.

These changes are planned as a result of the evidence that tragic fires are continuing throughout the country in residential buildings. The emphasis of these proposed fire standards is on providing increased life safety by the greater use of fire detection and extinguishing devices and additional controls on the operation of elevators.

It is expected that the proposed revisions to the Minimum Property Standards for fire will ultimately be formally adopted by the Department. They will then be incorporated into the Department's regulations and will be available, together with the other Minimum Property Standards, for purchase by all interested persons.

The public is invited to comment on these proposed revised fire protection standards, copies of which are available for public inspection in both the Office of Technical and Credit Standards, Architecture and Engineering Division, Room 5224, and the Office of General Counsel, Rules Docket Clerk, Room 10256, Department of Housing and Urban Development, 451 Seventh Street SW., Washington, DC 20410. These proposed revised standards are also available in each HUD Regional, Area, and Insuring Office. Comments should be filed in triplicate, using the above docket number and title, with the Rules Docket Clerk at the address stated above. All relevant material received on or before March 29, 1973, will be considered. Copies of comments submited will be available for examination by interested persons during business hours, both before and after the closing, at the office of the Rules Docket Clerk.

Issued at Washington, D.C., February 2, 1973.

JOHN L. GANLEY,
Deputy Assistant Secretary for Housing Production and Mortgage Credit.

[FR Doc.73-4206 Filed 3-2-73;8:45 am]

Office of Interstate Land Sales Registration

[Docket No. N-73-142; Administrative Division Docket No. 2-278]

CRYSTAL HILLS, ET AL.

Notice of Hearing

Notice is hereby given that.

1. Crystal Hills Development Co., its officers and agents, hereinafter referred to as "Respondent," being subject to the provisions of the Interstate Land Sales Full Disclosure Act (Public Law 90-448) (15 U.S.C. 1701 et seq.), received a Notice of Proceedings and Opportunity for Hearing dated January 4, 1973, which was sent to the developer pursuant to 15 U.S.C. 1706(d) and CFR 1710.45(b)(1) informing the developer of information obtained by the Office of Interstate Land Sales Registration showing that a change had occurred which affected material facts in the Developer's Statement of Record for Crystal Hills and the failure of the developer to amend the pertinent sections of the Statement of Record and Property Report.

2. The Respondent filed an answer dated January 19, 1973, in answer to the allegations of the Notice of Proceedings and Opportunity for a Hearing.

3. In said answer the Respondent requested a hearing on the allegations contained in the Notice of Proceedings and Opportunity for a Hearing.

4. Therefore, pursuant to the provisions of 15 U.S.C. 1706(d) and 24 CFR 1720.160(b), *It is hereby ordered*, That a public hearing for the purpose of taking evidence on the questions set forth in the Notice of Proceedings and Opportunity for Hearing will be held before Paul N. Pfeiffer, Administrative Law Judge, in Room 7233, Department of HUD Building, 451 Seventh Street SW., Washington, DC, on March 6, 1973, at 10 a.m.

The following time and procedure is applicable to such hearing: All affidavits and a list of all witnesses are requested to be filed with the Hearing Clerk, HUD Building, Room 10150, Washington, D.C. 20410, on or before February 28, 1973.

5. The Respondent is hereby notified that failure to appear at the above scheduled hearing shall be deemed a default and the proceeding shall be determined against Respondent, the allegations of which shall be deemed to be true, and an order suspending the statement of record, herein identified shall be issued pursuant to 24 CFR 1710.45(b)(1).

This notice shall be served upon the respondent forthwith pursuant to 24 CFR 1720.440.

Dated: February 23, 1973.

By the Secretary.

GEORGE K. BERNSTEIN,
Interstate Land Sales Administrator.

[FR Doc.73-4096 Filed 3-2-73;8:45 am]

[Docket No. N-73-141; Administrative D Division Docket No. Z-276]

RIVER'S BEND ESTATES, ET AL.

Notice of Hearing

Notice is hereby given that:

1. River's Bend Estates, Inc., its officers and agents, hereinafter referred to as "Respondent," being subject to the provisions of the Interstate Land Sales Full Disclosure Act (Public Law 90-448) (15 U.S.C. 1701 et seq.), received a Notice of Proceedings and Opportunity for hearing dated January 4, 1973, which was sent to the developer pursuant to 15 U.S.C. 1706(d) and 24 CFR 1710.45(b)(1) informing the developer of information obtained by the Office of Interstate Land Sales Registration showing that a change had occurred which affected material facts in the developer's Statement of Record for River's Bend Estates and the failure of the developer to amend the pertinent sections of the Statement of Record and Property Report.

2. The Respondent filed an answer received January 24, 1973, in answer to the allegations of the Notice of Proceedings and Opportunity for a Hearing.

3. In said answer the Respondent requested a hearing on the allegations contained in the Notice of Proceedings and Opportunity for a hearing.

4. Therefore, pursuant to the provisions of 15 U.S.C. 1706(d) and 24 CFR 1720.160(b), *It is hereby ordered*, That a public hearing for the purpose of taking evidence on the questions set forth in the Notice of Proceedings and Opportunity for Hearing will be held before Paul N. Pfeiffer, Administrative Law Judge, in Room 7233, Department of HUD Building, 451 7th Street SW., Washington, DC, on March 6, 1973, at 2 p.m.

The following time and procedure is applicable to such hearing: All affidavits and a list of all witnesses are requested to be filed with the Hearing Clerk, HUD Building, Room 10150, Washington, D.C. 20410, on or before February 28, 1973.

5. The Respondent is hereby notified that failure to appear at the above scheduled hearing shall be deemed a default and the proceeding shall be determined against Respondent, the allegations of which shall be deemed to be true, and an order suspending the statement of record, herein identified, shall be issued pursuant to 24 CFR 1710.45(b)(1).

This notice shall be served upon the Respondent forthwith pursuant to 24 CFR 1720.440.

Dated: February 23, 1973.

By the Secretary.

GEORGE K. BERNSTEIN,
Interstate Land Sales Administrator.

[FR Doc.73-4095 Filed 3-2-73;8:45 am]

ATOMIC ENERGY COMMISSION

[Dockets Nos. 50-295, 50-304]

COMMONWEALTH EDISON CO.

Notice and Order for Final Prehearing Conference

In the matter of Commonwealth Edison Co. (Zion Station, Units 1 and 2), Dockets Nos. 50-295, 50-304.

Take notice that pursuant to the Commission's rules of practice, the Atomic Safety and Licensing Board (the Board) assigned to this proceeding will hold a final prehearing conference on March 12, 1973, in Washington, D.C. This prehearing conference will start at 11 a.m., e.s.t., at the following address:

U.S. District Court, Courtroom 24, Third and Constitution Avenue NW., Washington, D.C. 20001.

At the subject conference, the parties, by their attorneys, will:

1. Report on the status of discovery;

2. Discuss the needs for further discovery, and the time required for such discovery, if any; and

3. Submit oral or written arguments on those contentions upon which the parties have thus far failed to agree concerning